SeaCrest Wealth Management’s Editas Medicine EDIT Stock Holding History

SeaCrest Wealth Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,249	Closed	-$15K	–	859
2022 Q2	$15K	Buy	+1,249	New	+$16.7K	﹤0.01%	1599
2021 Q3	–	Sell	-7,073	Closed	-$401K	–	693
2021 Q2	$401K	Sell	7,073 -18,474	-72%	-$682K	0.05%	407
2021 Q1	$1.07M	Buy	25,547 +1,309	+5%	+$74.6K	0.14%	161
2020 Q4	$1.7M	Buy	+24,238	New	+$996K	0.24%	89
2020 Q3	–	Sell	-9,527	Closed	-$282K	–	595
2020 Q2	$282K	Buy	+9,527	New	+$249K	0.05%	408
2019 Q2	–	Sell	-221	Closed	-$5K	–	867
2019 Q1	$5K	Hold	221	–	–	﹤0.01%	1709
2018 Q4	$5K	Sell	221 -300	-58%	-$8.16K	﹤0.01%	1686
2018 Q3	$17K	Sell	521 -835	-62%	-$27K	﹤0.01%	1442
2018 Q2	$49K	Buy	+1,356	New	+$48K	0.01%	996

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SeaCrest Wealth Management's EDIT Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Editas Medicine (EDIT) in Q3 2022, closing a stake of 1,249 shares — an estimated $15K sold.

SeaCrest Wealth Management first reported a position in EDIT in Q2 2018 and held it in 9 quarters. The position peaked at $1.7M in Q4 2020. 264 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

SeaCrest Wealth Management reported no remaining Editas Medicine position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 1,249 Editas Medicine shares in Q3 2022, an estimated $15K.
SeaCrest Wealth Management first reported a position in Editas Medicine in Q2 2018 and held it in 9 quarters.
SeaCrest Wealth Management's Editas Medicine position peaked at $1.7M in Q4 2020.
264 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.